Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration

Experimental Neurology

Volumn 146, Issue 1, 1997, Pages 135-141

  Palfi, Stéphane ^a   Riche, Danielle ^b   Brouillet, Emmanuel ^a   Guyot, Marie Caroline ^a   Mary, Véronique ^c   Wahl, Florence ^c   Peschanski, Marc ^b   Stutzmann, Jean Marie ^c   Hantraye, Philippe ^a  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b INSERM   (France)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RILUZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABOON; CAUDATE NUCLEUS; CORPUS STRIATUM; DRUG EFFECT; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PUTAMEN;

EID: 0031193501     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6520     Document Type: Article

References (25)

1. 1. Barbeito, L., A. Chéramy, G. Godeheu, J. M. Desce, and J. Glowinski. 1990. Glutamate receptors of a quisqualate-kainate subtype are involved in the presynaptic regulation of dopamine release in the cat caudate nucleus in vivo. Eur. J. Neurosci. 2: 304-311.
2. 2. Becquet, D., M. Faudon, and F. Hery. 1989. Effect of thalamic parafascicularis nucleus stimulation in regulation of serotoninergic transmission in the cat caudate nucleus: Involvement of autoreceptors in the dorsalis raphe nucleus. Neuroscience 33: 263-300.
3. 3. Benavides, J., J. C. Camelin, N. Mitrani, F. Flamand, A. Uzan, I. L. Legrand, G. Gueremy, and G. Le Fur. 1985. 2-amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory acid neurotransmission. II. Biochemical properties. Neuropharmacology 24: 1085-1092.
4. 4. Benoit, E., and D. Escande. 1991. Riluzole specifically blocks inactivated Na channels in myelinated nerve fibres. Pflugers Arch. 419: 603-609.
5. 5. Bensimon, G., L. Lacomblez, V. Meininger, and the ALS/Riluzole study group. 1994. A controlled trial of riluzole in amyotrophic lateral sclerosis. N. Engl. J. Med. 330: 585-591.
6. 6. Boireau, A., P. Dubédat, F. Bordier, C. Peny, J-M. Miquet, G. Durand, M. Meunier, and A. Doble. 1994. Riluzole and experimental parkinsonism: Antagonism of MPTP-induced decrease in central dopamine levels in mice. NeuroReport 5: 2657-2660.
7. 7. Brouillet, E., P. Hantraye, R. J. Ferrante, R. Dolan, A. Leroy-Willig, N. W. Kowall, and M. F. Beal. 1995. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl. Acad. Sci. USA 92: 7105-7109.
8. 8. Chéramy, A., R. Romo, G. Godeheu, P. Baruch, and J. Glowinski. 1986. In vivo presynaptic control of dopamine release in the cat caudate nucleus. II. Facilitatory or inhibitory influence of L-glutamate. Neuroscience 19: 1081-1090.
9. 9. Chéramy, A., L. Barbeito, G. Godeheu, and J. Glowinski. 1992. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci. Lett. 147: 209-212.
10. 10. Debono, M. W., J. Le Guern, T. Canton, A. Doble, and L. Pradier. 1993. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur. J. Pharmacol. 235: 283-289.
11. 11. Dolan, R., J. McIntyre, E. Brouillet, M. Varastet, M. Maziere, and P. Hantraye. 1993. Analysis of locomotor activity in nonhuman primate models of Parkinsons and Huntingtons diseases. Soc. Neurosci. Abstr. 19: 403.
12. 12. Estevez, A., J. M. Stutzmann, and L. Barbeito. 1995. Protective effect of riluzole on excitatory amino acid-mediated neurotoxicity in motoneuron-enriched cultures. Eur. J. Pharmacol. 280: 47-53.
13. 13. Hantraye, P., D. Riche, M. Maziere, and O. Isacson. 1990. A primate model of Huntington's disease: Behavioral and anatomical studies of unilateral excitotoxic lesions of the caudateputamen in the baboon (1990). Exp. Neurol. 108: 91-105.
14. 14. Hantraye, P., D. Riche, M. Maziere, and O. Isacson. 1992. Intrastriatal grafting of fetal striatal cross-species cells ameliorates abnormal movements in a primate model of Huntington's disease. Proc. Natl. Acad. Sci. USA 89: 4187-4191.
15. 15. Hubert, J. P., and A. Doble. 1989. Ibotenic acid stimulates D-(3H) aspartate release from cultured cerebellar granule cells. Neurosci. Lett. 96: 345-350.
16. 16. Jones-Humble, S. A., P. F. Morgan, and B. R. Cooper. 1994. The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP animal model of Parkinson's disease. Life Sci. 54: 245-252.
17. 17. Malgouris, C., F. Bardot, M. Daniel, F. Pellis, J. Rataud, A. Uzan, J. C. Blanchard, and P. M. Laduron. 1989. Riluzole, a novel antiglutamate, prevents memory loss and hippocampal damage in ischemic gerbils. J. Neurosci. 9: 3720-3727.
18. 18. Mary, V., F. Wahl, and J. M. Stutzmann. 1995. Effect of riluzole on quinolinate-induced neuronal damage in rats: Comparison with blockers of glutamatergic neurotransmission. Neurosci. Lett. 201: 92-96.
19. 19. Martin, D., M. A. Thompson, and J. V. Nadler. 1993. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur. J. Pharmacol. 250: 473-476.
20. 20. Mizoule, J., B. Meldrum, M. Mazadier, M. Croucher, C. Ollat, A. Uzan, J. J. Legrand, C. Gueremy, and G. Le Fur. 1985. 2-amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid transmission. I. Anticonvulsant properties. Neuropharmacology 24: 767-773.
21. 21. Pratt, J., J. Rataud, F. Bardot, M. Roux, J. C. Blanchard, P. M. Laduron, and J. M. Stutzmann. 1992. Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischemia. Neurosci. Lett. 140: 225-230.
22. 22. Palfi, S., R. J. Ferrante, E. Brouillet, M. F. Beal, R. Dolan, M. C. Guyot, M. Peschanski, and P. Hantraye. 1996. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J. Neurosci. 16: 3019-3025.
23. 23. Samuel, D., O. Blin, N. Dusticier, and A. Nieoullon. 1992. Effects of 2-amino-6-trifluoromethoxy benzothiazole on striatal neurochemical markers in the rat, with special reference to the dopamine, choline, GABA and glutamate synaptosomal high affinity uptake system. Fund. Clin. Pharmacol. 6: 177-184.
24. 24. Stutzmann, J. M., and A. Doble. 1994. Blockade of glutamatergic transmission and neuroprotection: The strange case of riluzole. Pages 205-214 in (G. Jolles, and J. M. Stutzmann, Eds.), Neurodegenerative Diseases. Academic Press, London.
25. 25. Wahl, F., M. Allix, M. Plotkine, and R. G. Boulu. 1993. Effect of riluzole on focal cerebral ischemia in rats. Eur. J. Pharmacol. 230: 209-214.